Heart failure & cardiomyopathiesSecondary analysis
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF
- pre-specified Bayesian analysis
- robust meta-analytic predictive (MAP) prior
- vague priors and informative MAP priors
Authors' conclusion
The non-steroidal MRA finerenone reduced the rate of cardiovascular death and total heart failure events under both frequentist and Bayesian inference methods. The probability of benefit exceeded 80% for both cardiovascular and all-cause mortality with finerenone. Trial Registration: ClinicalTrials.gov Identifier: NCT04435626
Study context
- Population
- Patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) in the FINEARTS-HF trial
- Participants
- 6,001 patients
- Comparison
- finerenone vs. placebo
- Primary endpoint
- cardiovascular death and total heart failure events
Primary result
As reported in the abstract
Relative risk
0.83
95% credible interval (CrI) CI 0.74–0.94
finerenone vs placebo
RR 0.83 (95% credible interval (CrI) CI 0.74–0.94)
- Posterior probability of a ≥ 10% reduction in the primary event rate, incorporating prior evidence
- from 90% to 92%
Further findings
| Outcome | HR (95% CrI CI) | |
|---|---|---|
| cardiovascular death | 0.93 (0.79–1.10) | |
| all-cause mortality | 0.94 (0.83–1.06) | |
| 0.512Hazard ratio (log scale) |
- cardiovascular death — Probability that finerenone reduced cardiovascular death
- 80%
- all-cause mortality — Probability that finerenone reduced all-cause mortality
- 85%
Original publication
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF. Eur Heart J Cardiovasc Pharmacother. Published 16 February 2026. doi:10.1093/ehjcvp/pvag010
Summarised from the published abstract; every number is checked against it